Bristol Myers Squibb’s CAR T Cell Remedy Breyanzi Authorised by the U.S. Meals and Drug Administration for Relapsed or Refractory Follicular Lymphoma
95.7% of sufferers responded to Breyanzi within the TRANSCEND FL trialBreyanzi offered…
Key highlights from Bristol Myers Squibb’s (BMY) Q1 2024 earnings outcomes
Bristol Myers Squibb (NYSE: BMY) reported first quarter 2024 earnings outcomes at…
